Market Indices
Sector Heatmap
CRSP — CRISPR Therapeutics AG
NasdaqCRISPR Therapeutics AG
- O
- 56.45
- H
- 57.58
- L
- 54.09
- V
- 1.13M
CRSP — Latest News & Headlines
20 StoriesCRISPR Therapeutics (Nasdaq:CRSP) - Stock Analysis - Simply Wall Street
CRISPR Therapeutics (Nasdaq:CRSP) - Stock Analysis Simply Wall Street
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Moves 1.20%: What You Should Know Yahoo Finance
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. - Barchart.com
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. Barchart.com
Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
Ali Behbahani Sells 13,679 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock MarketBeat
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history - Yahoo Finance Australia
CRISPR Therapeutics AG (CRSP) stock price, news, quote and history Yahoo Finance Australia
An experimental scleroderma treatment uses immune cells with changed genes. Early data will be presented Nov. 8. - Stock Titan
An experimental scleroderma treatment uses immune cells with changed genes. Early data will be presented Nov. 8. Stock Titan
Gene editing stocks fall after Anthropic’s CRISPR-like discovery - Seeking Alpha
Gene editing stocks fall after Anthropic’s CRISPR-like discovery Seeking Alpha
CRSP 260925 54.00C (CRSP260925C54000) Stock Options Chain | Quotes & News - Moomoo
CRSP 260925 54.00C (CRSP260925C54000) Stock Options Chain | Quotes & News Moomoo
CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base - Simply Wall Street
CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base Simply Wall Street
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger - Yahoo Finance
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As Book Value Questions Linger Yahoo Finance
CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 - Stock Titan
CRISPR Therapeutics (CRSP) director exercises options, then sells 13,679 shares around $57 Stock Titan
CRISPR Therapeutics (CRSP) Stock May Trade At A Premium To Book Value - Simply Wall Street
CRISPR Therapeutics (CRSP) Stock May Trade At A Premium To Book Value Simply Wall Street
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why Yahoo Finance
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. - Stock Titan
CRISPR Therapeutics (CRSP) counsel exercised options and sold 10,400 shares under a trading plan. Stock Titan
Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution - Stock Titan
Director at CRISPR Therapeutics (CRSP) gets stock in no-cash fund distribution Stock Titan
Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale - Stock Titan
Insider plans $626K CRISPR Therapeutics (NASDAQ: CRSP) stock sale Stock Titan
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know Yahoo Finance
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon - Yahoo Finance
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon Yahoo Finance
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon - 24/7 Wall St.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon 24/7 Wall St.
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of Company Stock MarketBeat